WHAT: The fight to contain the 2013-16 Ebola outbreak in West Africa was hampered by the lack of an effective treatment or vaccine. Researchers funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have studied the blood of an Ebola survivor, searching for human antibodies that might effectively treat not only people infected with Ebola virus, but those infected with related viruses as well. Now the researchers have identified two such antibodies that hold promise as Ebola treatments.
Ebola and Marburg News Releases
Analysis of daily gene activation in a patient with severe Ebola virus disease cared for at the National Institutes of Health (NIH) in 2015 found changes in antiviral and immune response genes that pinpointed key transition points in the response to infection. The changes included a marked decline in antiviral responses that correlated with clearance of virus from white blood cells. The analysis also showed that the preponderance of host responses shifted rapidly from activation of genes involved in cell damage and inflammation toward those linked to promotion of cellular and organ repair.
The French National Institute of Health and Medical Research (Inserm), the US National Institutes of Health (NIH) and the London School of Hygiene & Tropical Medicine (LSHTM), in collaboration with health authorities in Guinea and Liberia, are launching a large clinical trial of candidate Ebola vaccines under the aegis of the PREVAC international consortium (Partnership for Research on Ebola VACcination).
Scientists funded by the National Institutes of Health have found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus. Although the Marburg and Ravn viruses are less familiar than Ebola virus, both can resemble Ebola in symptoms and outcomes in people, and both lack preventive and therapeutic countermeasures.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association. The investigational vaccines included Ad26.ZEBOV, developed by Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo, developed by Bavarian Nordic.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The study, which is being conducted at the NIH Clinical Center in Bethesda, Maryland, will examine the experimental vaccine’s safety and ability to generate an immune response.
A new mouse model of early Ebola virus (EBOV) infection has shown National Institutes of Health (NIH) scientists and colleagues how early responses of the immune system can affect development of EBOV disease. The model could help identify protective immune responses as targets for developing human EBOV therapeutics.
Scientists from NIH’s National Institute of Allergy and Infectious Diseases led the study with colleagues from the University of Washington and Columbia University.
A clinical trial to evaluate the experimental Ebola treatment ZMapp found it to be safe and well-tolerated; however, because of the waning Ebola epidemic, the study enrolled too few people to determine definitively whether it is a better treatment for Ebola virus disease (EVD) than the best available standard of care alone. The findings from the randomized, controlled trial known as PREVAIL II appear in the October 13th issue of The New England Journal of Medicine.
Scientists funded by the National Institutes of Health (NIH) have successfully treated monkeys several days after the animals were infected with Sudan ebolavirus (SUDV). The study is important, according to the researchers, because no proven treatments against SUDV exist and little is known about the window of opportunity for treating the infection.
People infected with Ebola virus were 20 percent more likely to survive if they were co-infected with malaria-causing Plasmodium parasites, according to data collected at an Ebola diagnostic laboratory in Liberia in 2014-15. Moreover, greater numbers of Plasmodium parasites correlated with increased rates of Ebola survival, according to a dozen collaborating research groups in the new study, published in Clinical Infectious Diseases.
The Partnership for Research on Ebola Virus in Liberia (PREVAIL), a U.S.-Liberia joint Clinical Research Partnership, today announced the opening of PREVAIL IV, a treatment trial for men who have survived Ebola virus disease (EVD) but continue to have evidence of Ebola virus genetic material, RNA, in their semen.
An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April 19th issue of the Journal of the American Medical Association.
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody—a protein that attacks viruses—isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection.
Preliminary findings from PREVAIL III, a study of Ebola virus disease (EVD) survivors being conducted in Liberia, indicate that both Ebola survivors and their close contacts have a high burden of illness. However, the prevalence of eye, musculoskeletal, and neurological complications was greater among the individuals who survived EVD.
In a special issue on Ebola for the journal Clinical Trials, leading researchers from across the globe, including from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), describe in a series of articles the challenges of conducting ethically and scientifically sound clinical research during the 2014-2015 Ebola outbreak in West Africa and lessons learned for future outbreaks.
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National Institutes of Health (NIH) scientists and colleagues.
National Institutes of Health scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain when given at least 7 days before exposure, and partially protects them if given 3 days prior.
An experimental aerosolized (inhalable) vaccine fully protected nonhuman primates against Ebola virus disease. Aerosolized vaccines are delivered using a nebulizer, a device that transforms liquid into a mist that can be inhaled into the lungs.
The Makona strain of Ebola virus circulating in West Africa for the past year takes roughly two days longer to cause terminal disease in an animal model compared to the original 1976 Mayinga strain isolated in Central Africa, according to a new National Institutes of Health report.
Scientists from the National Institute of Allergy and Infectious Diseases and colleagues have identified 80 currently licensed drugs that demonstrated antiviral activity against Zaire ebolavirus in laboratory testing.
Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses-the first to be completed in an African country-showed that they were safe and induced immune responses in healthy volunteers.
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a phase 1 clinical trial conducted by researchers from the National Institutes of Health.
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.
The National Institute of Allergy and Infectious Diseases today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses.